These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1348452)

  • 41. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Preparation of buspirone hydrochloride buccal adhesive tablet and study on its drug release mechanism].
    Du Q; Ping QN; Liu GJ
    Yao Xue Xue Bao; 2002 Aug; 37(8):653-6. PubMed ID: 12567784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and evaluation of buccoadhesive propranolol hydrochloride tablet formulations: effect of fillers.
    Akbari J; Nokhodchi A; Farid D; Adrangui M; Siahi-Shadbad MR; Saeedi M
    Farmaco; 2004 Feb; 59(2):155-61. PubMed ID: 14871508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of release of hydroxypropylmethyl cellulose on single and bilayer sustained-release matrix tablets].
    Yang YP; Wang MY; Chang JB; Guo MT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):291-6. PubMed ID: 23591354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
    Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
    Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modified release bi-layered tablet of melatonin using beta-cyclodextrin.
    Kumar A; Agarwal SP; Khanna R
    Pharmazie; 2003 Sep; 58(9):642-4. PubMed ID: 14531461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NMR imaging investigations of drug delivery devices using a flow-through USP dissolution apparatus.
    Fyfe CA; Grondey H; Blazek-Welsh AI; Chopra SK; Fahie BJ
    J Control Release; 2000 Jul; 68(1):73-83. PubMed ID: 10884581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An animal model based on the Sprague Dawley rat for the evaluation of ototoxicity.
    Martini A; Hatzopoulos S; Rubini R; Di Stefano M; Albertin A; Govoni E
    Ann N Y Acad Sci; 1999 Nov; 884():85-98. PubMed ID: 10842586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
    Cutler NR; Reines SA; McLean LF; Sramek JJ; Porras AG; Hand EL
    Clin Pharmacokinet; 1992 Mar; 22(3):223-30. PubMed ID: 1348452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
    Lieberman A; Chin L; Baumann G
    Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC.
    Ishikawa T; Watanabe Y; Takayama K; Endo H; Matsumoto M
    Int J Pharm; 2000 Jul; 202(1-2):173-8. PubMed ID: 10915941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
    Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
    Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation.
    Miyazaki S; Kawasaki N; Nakamura T; Iwatsu M; Hou WM; Attwood D
    Int J Pharm; 2000 Aug; 204(1-2):127-32. PubMed ID: 11011995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.